

# CONTENTS

Vol.42 No.2 Mar 2011

Japanese Journal of Clinical Pharmacology  
and Therapeutics

## **Forum**

- Questionnaire on the Medical Professionals' Assessment of the Description Order of  
Package Insert Contents and Appreciation of Conditions for Drug Approval Mariko IWASE, et al. 33

## **Report**

- Report of Trainee of the Foreign Clinical Pharmacology Training Program : No. 1 Atsushi SAKURABA 41  
Report of Trainee of the Foreign Clinical Pharmacology Training Program : No. 2 Takahiro OHARA 45

## **Proceedings of the 31th Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics**

- Contents 49  
Symposium 16 "Dose Difference in Multi-National Clinical Trial and Its Evidence" 53  
Symposium 17 "Oral Bacteria-Related Systemic Diseases : Up-to-Date" 63  
Symposium 20 "Scrutinizing the Current Educational Contents for Clinical Pharmacology  
in the Model Core-Curriculums for Medical Doctors and Pharmacists" 73  
Symposium 22 "How to Boost Early-Phase Exploratory Trials (FIM & POC Studies) in Japan" 83  
Symposium 24 "Challenges in New Drug Development" 93  
Symposium 25 "Current Status of Chronomedicine" 103

**Minutes of JSCPT Administrative Meetings** 41E

**Drug Information** 67E

**Information for Authors** 71E

**Announcements** 73E

**Proceedings of the 31th Annual Meeting of the Japanese Society of Clinical Pharmacology  
and Therapeutics**

December 1-3, 2010 (Kyoto)

President: Ken-ichi INUI (Emeritus Professor, Kyoto University/President, Kyoto Pharmaceutical University)

**Symposium 16 “Dose Difference in Multi-National Clinical Trial and Its Evidence”**

Summary	<b>Kanji TAKADA, et al.</b>	53
S16-1 Difference on Clinical Dose between Three Areas and Pharmacokinetics of Drugs	<b>Eri OKUKDA, et al.</b>	55
S16-2 Ethnic Factors in Drug Dosing and Evidence-Based Medicine in Global Clinical Trials	<b>Tetsuya NAKAMURA</b>	57
S16-3 International Differences in Approved and Used Dosing for Drugs	<b>Masahiro NAGAI</b>	59
S16-4 Dose Selection in Global Clinical Trials --From the Reviewer's Viewpoint--	<b>Kaori SHINAGAWA</b>	61

**Symposium 17 “Oral Bacteria-Related Systemic Diseases : Up-to-Date”**

Summary	<b>Kazuo UMEMURA, et al.</b>	63
S17-1 Periodontal Diseases and 4 Systemic Diseases	<b>Atsuo AMANO, et al.</b>	65
S17-2 Role of Oral Bacteria as a Risk Factor for NASH	<b>Koichiro WADA, et al.</b>	67
S17-3 Discovery and Clarification of the Stroke Induced Oral Bacteria	<b>Kazuya Hokamura, et al.</b>	69
S17-4 A Possible New Risk Factor for Cerebral Stroke, a Dental Caries Pathogen with Collagen-Binding Protein and Inhibitory Activity of Platelet Aggregation	<b>Tokutaro TANAKA, et al.</b>	71

**Symposium 20 “Scrutinizing the Current Educational Contents for Clinical Pharmacology  
in the Model Core-Curriculums for Medical Doctors and Pharmacists”**

Summary	<b>Hirotoishi ECHIZEN, et al.</b>	73
S20-1 Current Status and Future of Medical Education about Drug Therapy	<b>Akio FUJIMURA</b>	75
S20-2 Education of Individualized Drug Therapy: From School of Pharmacy	<b>Takashi SUZUKI</b>	77
S20-3 The Education of Pharmaceutical Development in Medical Faculties	<b>Kyoichi OHASHI</b>	79
S20-4 Make an Inspection of Clinical Pharmacology in the “Model Core Curriculum for Pharmaceutical Education”	<b>Makoto WATANABE</b>	81

**Symposium 22 “How to Boost Early-Phase Exploratory Trials (FIM & POC Studies) in Japan”**

S22-1 Summary	<b>Ryuichi KATO, et al.</b>	83
S22-2 Measures for Promoting Early-Stage Exploratory Clinical Studies and Preventing Japanese Clinical Trials' Hollowing Out --From the View Point of Pharma Industries--	<b>Osamu INAGAKI</b>	85
S22-3 How to Boost Early-Phase Exploratory Trials(FIM & POC Studies) in Japan --From Foreign-Based Pharma Industry Perspective--	<b>Masaru IWASAKI</b>	87
S22-4 Role of Academic Institutions to Encourage Early Phase Exploratory Clinical Trials	<b>Hiroshi WATANABE</b>	89
S22-5 From the Viewpoint of Regulatory Science	<b>Masanobu YAMADA</b>	91

**Symposium 24 “Challenges in New Drug Development”**

Summary	<b>Satoshi TOYOSHIMA, et al.</b>	93
S24-1 Current Project to Promote Development of Drugs of Unmet Medical Needs in Japan	<b>Kazuishi SEKINO</b>	95
S24-2 Global Clinical Trials : Current Situation of New Drug Review and Clinical Trial Consultation Meetings in PMDA	<b>Yuki ANDO</b>	97
S24-3 Current Situation of Research Project in China-Japan-Korea Tripartite Cooperation	<b>Yoshiaki UYAMA</b>	99
S24-4 Perspective of Benefit Risk Evaluation in Post-Marketing	<b>Junko SATO</b>	101

Symposium 25 “Current Status of Chronomedicine”

S25-1	Circadian Clock System and Chronotherapy	<b>Hitoshi OKAMURA</b>	103
S25-2	Development of a Predict Tool for Drug-Induced Psychiatric Diseases by Applying the Biological Clock System	<b>Kentarou USHIJIMA, et al.</b>	105
S25-3	Circadian Rhythm and Cardiovascular Disease	<b>Kazuomi KARIO</b>	107
S25-4	Chronotherapy and Circadian Rhythm of Rheumatoid Arthritis	<b>Hideto TO</b>	109